Selected research
Industry Research
Atypical Antipsychotic Drugs Industry Research Report 2026
Market perspective
The global Atypical Antipsychotic Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Atypical Antipsychotic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Atypical Antipsychotic Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Atypical Antipsychotic Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Atypical Antipsychotic Drugs include Sun Pharmaceutical Industries, Johnson and Johnson, Qilu Pharmaceutical, Novartis AG, Eil Lilly and Company, Pfizer, GlaxoSmithKline, AstraZeneca and Sumitomo Dainippon Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Atypical Antipsychotic Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Atypical Antipsychotic Drugs Market by Company
Sun Pharmaceutical Industries
Johnson and Johnson
Qilu Pharmaceutical
Novartis AG
Eil Lilly and Company
Pfizer
GlaxoSmithKline
AstraZeneca
Sumitomo Dainippon Pharma
Sanis Health
Cardinal Health
Bristol-Myers Squibb Company
Allergan
Atypical Antipsychotic Drugs Segment by Type
Olanzapine
Quetiapine
Risperidone
Ziprasidone
Others
Atypical Antipsychotic Drugs Segment by Application
Schizoaffective Disorder
Schizophrenia
Bipolar I Disorder
Major Depressive Disorder (MDD)
Atypical Antipsychotic Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Atypical Antipsychotic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Atypical Antipsychotic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Atypical Antipsychotic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Atypical Antipsychotic Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Atypical Antipsychotic Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Atypical Antipsychotic Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Olanzapine
- Quetiapine
- Risperidone
- Ziprasidone
- Others
Applications
- Schizoaffective Disorder
- Schizophrenia
- Bipolar I Disorder
- Major Depressive Disorder (MDD)
Companies covered
- Sun Pharmaceutical Industries
- Johnson and Johnson
- Qilu Pharmaceutical
- Novartis AG
- Eil Lilly and Company
- Pfizer
- GlaxoSmithKline
- AstraZeneca
- Sumitomo Dainippon Pharma
- Sanis Health
- Cardinal Health
- Bristol-Myers Squibb Company
- Allergan
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Atypical Antipsychotic Drugs Market Size (2021-2032)
- 2.2.2 Global Atypical Antipsychotic Drugs Sales (2021-2032)
- 2.2.3 Global Atypical Antipsychotic Drugs Market Average Price (2021-2032)
- 2.3 Atypical Antipsychotic Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Olanzapine
- 2.3.3 Quetiapine
- 2.3.4 Risperidone
- 2.3.5 Ziprasidone
- 2.3.6 Others
- 2.4 Atypical Antipsychotic Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Schizoaffective Disorder
- 2.4.3 Schizophrenia
- 2.4.4 Bipolar I Disorder
- 2.4.5 Major Depressive Disorder (MDD)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Atypical Antipsychotic Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Atypical Antipsychotic Drugs Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Atypical Antipsychotic Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Atypical Antipsychotic Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Atypical Antipsychotic Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Atypical Antipsychotic Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Atypical Antipsychotic Drugs, Product Type & Application
- 3.8 Global Manufacturers of Atypical Antipsychotic Drugs, Established Date
- 3.9 Global Atypical Antipsychotic Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sun Pharmaceutical Industries
- 4.1.1 Sun Pharmaceutical Industries Company Information
- 4.1.2 Sun Pharmaceutical Industries Business Overview
- 4.1.3 Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Product Portfolio
- 4.1.5 Sun Pharmaceutical Industries Recent Developments
- 4.2 Johnson and Johnson
- 4.2.1 Johnson and Johnson Company Information
- 4.2.2 Johnson and Johnson Business Overview
- 4.2.3 Johnson and Johnson Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson and Johnson Atypical Antipsychotic Drugs Product Portfolio
- 4.2.5 Johnson and Johnson Recent Developments
- 4.3 Qilu Pharmaceutical
- 4.3.1 Qilu Pharmaceutical Company Information
- 4.3.2 Qilu Pharmaceutical Business Overview
- 4.3.3 Qilu Pharmaceutical Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Qilu Pharmaceutical Atypical Antipsychotic Drugs Product Portfolio
- 4.3.5 Qilu Pharmaceutical Recent Developments
- 4.4 Novartis AG
- 4.4.1 Novartis AG Company Information
- 4.4.2 Novartis AG Business Overview
- 4.4.3 Novartis AG Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novartis AG Atypical Antipsychotic Drugs Product Portfolio
- 4.4.5 Novartis AG Recent Developments
- 4.5 Eil Lilly and Company
- 4.5.1 Eil Lilly and Company Company Information
- 4.5.2 Eil Lilly and Company Business Overview
- 4.5.3 Eil Lilly and Company Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Eil Lilly and Company Atypical Antipsychotic Drugs Product Portfolio
- 4.5.5 Eil Lilly and Company Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Atypical Antipsychotic Drugs Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 GlaxoSmithKline
- 4.7.1 GlaxoSmithKline Company Information
- 4.7.2 GlaxoSmithKline Business Overview
- 4.7.3 GlaxoSmithKline Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 GlaxoSmithKline Atypical Antipsychotic Drugs Product Portfolio
- 4.7.5 GlaxoSmithKline Recent Developments
- 4.8 AstraZeneca
- 4.8.1 AstraZeneca Company Information
- 4.8.2 AstraZeneca Business Overview
- 4.8.3 AstraZeneca Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 AstraZeneca Atypical Antipsychotic Drugs Product Portfolio
- 4.8.5 AstraZeneca Recent Developments
- 4.9 Sumitomo Dainippon Pharma
- 4.9.1 Sumitomo Dainippon Pharma Company Information
- 4.9.2 Sumitomo Dainippon Pharma Business Overview
- 4.9.3 Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Product Portfolio
- 4.9.5 Sumitomo Dainippon Pharma Recent Developments
- 4.10 Sanis Health
- 4.10.1 Sanis Health Company Information
- 4.10.2 Sanis Health Business Overview
- 4.10.3 Sanis Health Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Sanis Health Atypical Antipsychotic Drugs Product Portfolio
- 4.10.5 Sanis Health Recent Developments
- 4.11 Cardinal Health
- 4.11.1 Cardinal Health Company Information
- 4.11.2 Cardinal Health Business Overview
- 4.11.3 Cardinal Health Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Cardinal Health Atypical Antipsychotic Drugs Product Portfolio
- 4.11.5 Cardinal Health Recent Developments
- 4.12 Bristol-Myers Squibb Company
- 4.12.1 Bristol-Myers Squibb Company Company Information
- 4.12.2 Bristol-Myers Squibb Company Business Overview
- 4.12.3 Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Product Portfolio
- 4.12.5 Bristol-Myers Squibb Company Recent Developments
- 4.13 Allergan
- 4.13.1 Allergan Company Information
- 4.13.2 Allergan Business Overview
- 4.13.3 Allergan Atypical Antipsychotic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Allergan Atypical Antipsychotic Drugs Product Portfolio
- 4.13.5 Allergan Recent Developments
5 Global Atypical Antipsychotic Drugs Market Scenario by Region
- 5.1 Global Atypical Antipsychotic Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Atypical Antipsychotic Drugs Sales by Region: 2021-2032
- 5.2.1 Global Atypical Antipsychotic Drugs Sales by Region: 2021-2026
- 5.2.2 Global Atypical Antipsychotic Drugs Sales by Region: 2027-2032
- 5.3 Global Atypical Antipsychotic Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Atypical Antipsychotic Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Atypical Antipsychotic Drugs Revenue by Region: 2027-2032
- 5.4 North America Atypical Antipsychotic Drugs Market Facts & Figures by Country
- 5.4.1 North America Atypical Antipsychotic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Atypical Antipsychotic Drugs Sales by Country (2021-2032)
- 5.4.3 North America Atypical Antipsychotic Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Atypical Antipsychotic Drugs Market Facts & Figures by Country
- 5.5.1 Europe Atypical Antipsychotic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Atypical Antipsychotic Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Atypical Antipsychotic Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Atypical Antipsychotic Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Atypical Antipsychotic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Atypical Antipsychotic Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Atypical Antipsychotic Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Atypical Antipsychotic Drugs Market Facts & Figures by Country
- 5.7.1 South America Atypical Antipsychotic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Atypical Antipsychotic Drugs Sales by Country (2021-2032)
- 5.7.3 South America Atypical Antipsychotic Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Atypical Antipsychotic Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Atypical Antipsychotic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Atypical Antipsychotic Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Atypical Antipsychotic Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Atypical Antipsychotic Drugs Sales by Type (2021-2032)
- 6.1.1 Global Atypical Antipsychotic Drugs Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Atypical Antipsychotic Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Atypical Antipsychotic Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Atypical Antipsychotic Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Atypical Antipsychotic Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Atypical Antipsychotic Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Atypical Antipsychotic Drugs Sales by Application (2021-2032)
- 7.1.1 Global Atypical Antipsychotic Drugs Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Atypical Antipsychotic Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Atypical Antipsychotic Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Atypical Antipsychotic Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Atypical Antipsychotic Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Atypical Antipsychotic Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Atypical Antipsychotic Drugs Value Chain Analysis
- 8.1.1 Atypical Antipsychotic Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Atypical Antipsychotic Drugs Production Mode & Process
- 8.2 Atypical Antipsychotic Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Atypical Antipsychotic Drugs Distributors
- 8.2.3 Atypical Antipsychotic Drugs Customers
9 Global Atypical Antipsychotic Drugs Analyzing Market Dynamics
- 9.1 Atypical Antipsychotic Drugs Industry Trends
- 9.2 Atypical Antipsychotic Drugs Industry Drivers
- 9.3 Atypical Antipsychotic Drugs Industry Opportunities and Challenges
- 9.4 Atypical Antipsychotic Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst